Research Use Only. Not for human or veterinary use. Not medical advice.

RC-IPA · Endocrine Signaling Research

RC-IPA vial (catalog image)

RC-IPA

Endocrine Signaling Research

Catalog code Research material Lyophilized format 5 mg vial
Presentation

Vial sizes for laboratory supply, not a protocol.

Pricing
Sign in
Researcher pricing for approved accounts
In stock
As listed on the public catalog, Nov 17, 2026
Add to cart
0 25 50 75
78 of 100

Popularity

High

Public interest index

Trending level+2% vs prior 30 days

Research: Literature Activity 5/10 · Modest (PubMed volume)

Data as of Nov 17, 2026 · Sources: Wikipedia pageviews, Reddit, X public mentions.

Measures online attention only. It is not a measure of quality, purity, efficacy, or safety.

Publications per year

Unique PubMed records grouped by publication year — a volume index, not a quality rating.

PubMed counts

Last updated Nov 17, 2026. 55 unique records for ipamorelin. 2026 is a partial year. Ten of the 2026 records are broader sports-peptide or survey papers that mention ipamorelin among other agents. Cards on this page use compound-specific papers, not those surveys. Source on PubMed

Key specifications

Catalog facts are taken from the live PEPTIDEA™ listing. Formula and molecular weight are from PubChem. Sequence is omitted here.

Catalog title
RC-IPA | Endocrine Signaling Research
Research focus
Endocrine Signaling Research
Also described as
Ipamorelin
Format
Lyophilized research peptide
Catalog status
In stock (public listing)
Presentations
5 mg vialCatalog sizes, not a protocol
Molecular formula
C38H49N9O5PubChem CID 9831659
Molecular weight
711.9PubChem average; exact mass 711.38566570
Receptor context
Described in the literature as a selective ghrelin receptor (GHS-R1a) agonistLiterature description; research context only
Sequence
Not reproduced hereSee primary literature / PubChem
Researcher access
Sign-in required to view pricing
PubMed records
55 uniqueQuery above, Nov 17, 2026

Catalog notes & use limitations

Research-catalog framing only. This section does not describe effects in people or study outcomes.

Catalog notes

Listed under Endocrine Signaling Research

RC-IPA appears in the PEPTIDEA™ Endocrine & Growth Factor Signaling Research collection with other endocrine-focus materials, including RC-TESA, RC-CJCIPA, and RC-KSP.

Distinct from the CJC/ipamorelin blend

RC-CJCIPA is catalogued separately as a multi-constituent product. This page is the single-compound ipamorelin listing.

5 mg vial

The catalog presentation is a 5 mg vial. That is a presentation of the research material, not a protocol.

Use limitations

Research use only

Not for human or veterinary use. Not a drug, not a cosmetic, and not medical advice. Not presented here as a treatment or weight-management product.

No outcome or dosing information

This page does not list administration amounts, schedules, or clinical results. Catalog vial sizes are presentations of the research material, not a protocol.

Confirm details from primary sources

Formula and molecular weight are cited from PubChem when a single compound applies; otherwise see the catalog notes. Sequence is omitted. Read the original papers for laboratory context — results stay in the original publications.

Specifications

Laboratory-catalog and public-chemistry details. Items without a cited source are marked.

Catalog titleRC-IPA | Endocrine Signaling Research
CategoryEndocrine Signaling Research (Endocrine & Growth Factor Signaling Research)
Associated namesIpamorelin
FormatLyophilized research peptide
Public catalog statusIn stock (as of Nov 17, 2026)
Catalog presentations5 mg vial — sizes of the research material, not a use protocol
Molecular formulaC38H49N9O5 (PubChem CID 9831659, retrieved Nov 17, 2026)
Molecular weight711.9 (PubChem average; exact mass 711.38566570)
InChIKeyNEHWBYHLYZGBNO-BVEPWEIPSA-N (PubChem)
Receptor contextPublished papers describe ipamorelin as a synthetic pentapeptide growth-hormone secretagogue and selective agonist of the ghrelin receptor (GHS-R1a). That is a mechanism-class description, not a use claim.
SequenceNot reproduced on this page. See primary literature and the PubChem record.
PricingVisible after researcher sign-in
PubChem CID 9831659 is cited for formula and mass. Sequence is omitted on this page.

Research literature

These are Peptidea-written summaries of selected publications, prepared so you can stay on peptidea.net. Each card describes what was studied — the research question, study type, and mechanism or setting. We do not restate results, endpoints, or protocols. Full papers remain with their publishers; a small PubMed source link is included only for citation.

Preclinical pharmacology

Raun et al.

European Journal of Endocrinology · 1998
Description of ipamorelin as a growth-hormone secretagogue

This paper introduces ipamorelin as a synthetic pentapeptide growth-hormone secretagogue and reports in-vitro and in-vivo pharmacology, including comparisons with earlier secretagogues.

Potency, selectivity, and other experimental results in the paper are not restated on this page.

Clinical pharmacology, healthy volunteers

Gobburu et al.

Pharmaceutical Research · 1999
Pharmacokinetic–pharmacodynamic study of ipamorelin in healthy volunteers

This paper reports pharmacokinetic and pharmacodynamic modeling of ipamorelin in healthy volunteers.

Infusion rates, pharmacokinetic parameters, and growth-hormone response values in the paper are not reproduced here.

Medicinal chemistry

Ankersen et al.

Journal of Medicinal Chemistry · 1998
A series of growth-hormone-releasing peptides derived from ipamorelin

This paper describes a medicinal-chemistry series of growth-hormone-releasing peptides derived from ipamorelin, including peptidomimetic modifications.

Structure–activity findings and any bioavailability discussion in the paper are not restated here.

Experimental, animal model

Greenwood-Van Meerveld et al.

Journal of Experimental Pharmacology · 2012
Ipamorelin in a rodent model of postoperative gastric dysmotility

This paper studied ipamorelin, described as a ghrelin-receptor agonist, in a rodent model of postoperative gastric dysmotility.

Transit measurements and any other experimental results in the paper are not reproduced on this page.

Experimental, animal model

Venkova et al.

Journal of Pharmacology and Experimental Therapeutics · 2009
Ipamorelin in a rodent model of postoperative ileus

This paper examined ipamorelin, described as a selective growth-hormone secretagogue and ghrelin-receptor agonist, in a rodent model of postoperative ileus, with measurements of gastrointestinal transit.

Transit findings and any other experimental results in the paper are not restated here.

Clinical — Phase 2, proof of concept

Beck, Sweeney, and McCarter

International Journal of Colorectal Disease · 2014
Randomized, proof-of-concept study in adults after bowel resection

This prospective, randomized, controlled, proof-of-concept phase 2 study evaluated ipamorelin in adults after bowel resection, in a postoperative gastrointestinal-motility research setting.

Endpoints, administration schedules, and any results reported in the paper are not reproduced on this page.

Original titles are omitted or neutralized when they use clinical-outcome wording. Counts and the optional source links use the query ipamorelin. Source on PubMed

Storage & handling

General laboratory-catalog guidance for layout purposes. Always follow the vial label and your institution’s written procedures.

  • Handle as a lyophilized research material intended for laboratory use only.
  • Store according to the conditions printed on the label and in any compound document provided to approved researchers.
  • Protect closed vials from moisture and unnecessary temperature swings.
  • If reconstitution is performed, use only the laboratory’s own written procedures. This page does not provide volumes, solvents, or working concentrations.
  • This material is not for human or veterinary use and is not medical advice.
No dosing, administration, or protocol instructions are included on this page.

Research Use Only. Not for human or veterinary use. Not medical advice. PEPTIDEA™ is a trademark of Grey Bug LLC.